Stocks › BMRN

BIOMARIN PHARMACEUTICAL INC

BMRN·Nasdaq·United States United States·USD
$60.41
-1.01 (-1.64%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
BMRN
BIOMARIN PHARMACEUTICAL INC · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
BMRNS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of BMRN by members of U.S. Congress · 25 on record
All congressional trades →
PoliticianStockTypeFiledTraded
Daniel S. GoldmanDaniel S. GoldmanHouse · D · NY BMRNBIOMARIN PHARMACEUTICAL INC · Stock Sale
$1,001 - $15,000
Apr 17, 2023 Mar 6, 2023 Filing ↗
Ro KhannaRo KhannaHouse · D · CA BMRNBIOMARIN PHARMACEUTICAL INC · Common Stock Sale
$1,001 - $15,000
Apr 7, 2023 Mar 14, 2023 Filing ↗
Ro KhannaRo KhannaHouse · D · CA BMRNBIOMARIN PHARMACEUTICAL INC · Common Stock Purchase
$1,001 - $15,000
Jan 6, 2023 Dec 6, 2022 Filing ↗
Ro KhannaRo KhannaHouse · D · CA BMRNBIOMARIN PHARMACEUTICAL INC · Common Stock Sale
$1,001 - $15,000
Jun 10, 2022 May 10, 2022 Filing ↗
Josh GottheimerJosh GottheimerHouse · D · NJ BMRNBIOMARIN PHARMACEUTICAL INC · Stock Sale
$1,001 - $15,000
Nov 15, 2021 Oct 18, 2021 Filing ↗
Gilbert Ray Cisneros, Jr.Gilbert Ray Cisneros, Jr.House · D · CA BMRNBIOMARIN PHARMACEUTICAL INC · Stock Purchase
$15,001 - $50,000
Jan 11, 2021 Dec 30, 2020 Filing ↗
Josh GottheimerJosh GottheimerHouse · D · NJ BMRNBIOMARIN PHARMACEUTICAL INC · Stock Purchase
$1,001 - $15,000
Nov 5, 2020 Oct 16, 2020 Filing ↗
Josh GottheimerJosh GottheimerHouse · D · NJ BMRNBIOMARIN PHARMACEUTICAL INC · Stock Sale
$1,001 - $15,000
Oct 13, 2020 Sep 15, 2020 Filing ↗
Josh GottheimerJosh GottheimerHouse · D · NJ BMRNBIOMARIN PHARMACEUTICAL INC · Stock Purchase
$1,001 - $15,000
Jan 6, 2020 Dec 11, 2019 Filing ↗
Josh GottheimerJosh GottheimerHouse · D · NJ BMRNBIOMARIN PHARMACEUTICAL INC · Stock Purchase
$1,001 - $15,000
Jan 6, 2020 Dec 16, 2019 Filing ↗
Alan S. LowenthalAlan S. LowenthalHouse · D · CA BMRNBIOMARIN PHARMACEUTICAL INC · Stock Sale
$506.27
Sep 1, 2019 Aug 15, 2019 Filing ↗
Alan S. LowenthalAlan S. LowenthalHouse · D · CA BMRNBIOMARIN PHARMACEUTICAL INC · Stock Sale
$1,001 - $15,000
Sep 1, 2019 Aug 15, 2019 Filing ↗
Alan S. LowenthalAlan S. LowenthalHouse · D · CA BMRNBIOMARIN PHARMACEUTICAL INC · Stock Sale
$1,001 - $15,000
Sep 1, 2019 Aug 14, 2019 Filing ↗
Alan S. LowenthalAlan S. LowenthalHouse · D · CA BMRNBIOMARIN PHARMACEUTICAL INC · Stock Sale
$217.10
Sep 1, 2019 Aug 14, 2019 Filing ↗
Ro KhannaRo KhannaHouse · D · CA BMRNBIOMARIN PHARMACEUTICAL INC · Common Stock Sale
$1,001 - $15,000
May 10, 2019 Apr 23, 2019 Filing ↗
Nicholas Van TaylorNicholas Van TaylorHouse · R · TX BMRNBIOMARIN PHARMACEUTICAL INC · Stock Sale
$1,001 - $15,000
Apr 15, 2019 Mar 25, 2019 Filing ↗
Alan S. LowenthalAlan S. LowenthalHouse · D · CA BMRNBIOMARIN PHARMACEUTICAL INC · Stock Purchase
$903.36
Jun 10, 2018 May 29, 2018 Filing ↗
Alan S. LowenthalAlan S. LowenthalHouse · D · CA BMRNBIOMARIN PHARMACEUTICAL INC · Stock Purchase
$1,001 - $15,000
May 3, 2018 Apr 26, 2018 Filing ↗
Alan S. LowenthalAlan S. LowenthalHouse · D · CA BMRNBIOMARIN PHARMACEUTICAL INC · Stock Purchase
$1,001 - $15,000
May 3, 2018 Apr 27, 2018 Filing ↗
Lamar SmithLamar SmithHouse · R · TX BMRNBIOMARIN PHARMACEUTICAL INC · Stock Sale
$1,001 - $15,000
Mar 7, 2018 Feb 12, 2018 Filing ↗
Alan S. LowenthalAlan S. LowenthalHouse · D · CA BMRNBIOMARIN PHARMACEUTICAL INC · Stock Purchase
$1,001 - $15,000
Jan 21, 2018 Jan 17, 2018 Filing ↗
Alan S. LowenthalAlan S. LowenthalHouse · D · CA BMRNBIOMARIN PHARMACEUTICAL INC · Stock Purchase
$1,001 - $15,000
Jan 21, 2018 Jan 18, 2018 Filing ↗
K. Michael ConawayK. Michael ConawayHouse · R · TX BMRNBIOMARIN PHARMACEUTICAL INC · Stock Sale
$1,001 - $15,000
Oct 12, 2016 Sep 12, 2016 Filing ↗
Thomas MacArthurThomas MacArthurHouse · R · NJ BMRNBIOMARIN PHARMACEUTICAL INC · Stock Sale
$1,001 - $15,000
Mar 5, 2015 Jan 27, 2015 Filing ↗
Lamar SmithLamar SmithHouse · R · TX BMRNBIOMARIN PHARMACEUTICAL INC · Stock Purchase
$1,001 - $15,000
Dec 8, 2014 Nov 14, 2014 Filing ↗

Whale Activity

Position changes in BMRN reported for 2026-09-30 by 633 institutional filers
Increased: 191New: 72Held: 98Decreased: 171Closed: 65No prior filing: 36
  • Increased191
  • New72
  • Held98
  • Decreased171
  • Closed65
  • No prior filing36
FilerSharesValueChange
BlackRock, Inc.20.7M$1.24Bincreased
PRIMECAP MANAGEMENT CO/CA/15.0M$899.3Mincreased
DODGE & COX14.6M$877.5Mdecreased
VANGUARD CAPITAL MANAGEMENT LLC8.7M$523.4Mdecreased
VANGUARD PORTFOLIO MANAGEMENT LLC8.4M$502.3Mdecreased
STATE STREET CORP8.3M$500.4Mincreased
FMR LLC7.3M$440.6Mincreased
VIKING GLOBAL INVESTORS LP7.2M$430.4Mdecreased
Deep Track Capital, LP6.4M$382.5Mincreased
Vestal Point Capital, LP5.5M$331.5Mdecreased
DIMENSIONAL FUND ADVISORS LP4.4M$263.9Mincreased
GEODE CAPITAL MANAGEMENT, LLC3.8M$225.4Mdecreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by BMRN insiders, by quarter · Form 4
-50.0K-25.0K025.0K50.0K2025 Q1: -9,6732025 Q12025 Q2: -2,0592025 Q22025 Q3: 02025 Q32025 Q4: 02025 Q42026 Q1: -48.9K2026 Q12026 Q2: -3,2812026 Q22026 Q3: -17.6K2026 Q32026 Q4: -5,1472026 Q4

Recent Insider Transactions

4,369 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
Friberg Gregory REVP, Chief R&D Officer Sale −5,147 $58.81 $303K Nov 18, 2026 Form 4 ↗
Plenge Robert MDirector Grant / award +6,140 $0.00 $0 Sep 10, 2026 Form 4 ↗
Davis George EricEVP, Chief Legal Officer Sale −17.6K $66.28 $1.2M Sep 2, 2026 Form 4 ↗
Countouriotis AthenaDirector Grant / award +7,490 $0.00 $0 Jun 2, 2026 Form 4 ↗
Walbert Timothy PDirector Grant / award +7,490 $0.00 $0 Jun 2, 2026 Form 4 ↗
Ho MaykinDirector Grant / award +7,490 $0.00 $0 Jun 2, 2026 Form 4 ↗
HOMBACH ROBERT J.Director Grant / award +7,490 $0.00 $0 Jun 2, 2026 Form 4 ↗
Enyedy Mark JDirector Grant / award +7,490 $0.00 $0 Jun 2, 2026 Form 4 ↗
Dere Willard HDirector Grant / award +7,490 $0.00 $0 Jun 2, 2026 Form 4 ↗
CLARK IAN TDirector Grant / award +7,490 $0.00 $0 Jun 2, 2026 Form 4 ↗
Bodem Barbara W.Director Grant / award +7,490 $0.00 $0 Jun 2, 2026 Form 4 ↗
ANDERSON ELIZABETH MDirector Grant / award +7,490 $0.00 $0 Jun 2, 2026 Form 4 ↗
Hubbard CristinEVP, Chief Commercial Officer Tax withholding −2,318 $50.20 $116K May 20, 2026 Form 4 ↗
Friberg Gregory REVP, Chief R&D Officer Sale −3,281 $53.85 $177K May 7, 2026 Form 4 ↗
Davis George EricEVP, Chief Legal Officer Tax withholding −1,273 $56.05 $71K Mar 18, 2026 Form 4 ↗
Guyer Charles GregEVP, Chief Technical Officer Tax withholding −1,693 $56.05 $95K Mar 17, 2026 Form 4 ↗
Mueller BrianEVP, Chief Financial Officer Tax withholding −2,117 $56.05 $119K Mar 17, 2026 Form 4 ↗
Hardy AlexanderChief Executive Officer · Director Tax withholding −4,252 $56.05 $238K Mar 17, 2026 Form 4 ↗
Hubbard CristinEVP, Chief Commercial Officer Tax withholding −1,245 $56.05 $70K Mar 17, 2026 Form 4 ↗
Friberg Gregory REVP, Chief R&D Officer Tax withholding −1,629 $56.05 $91K Mar 17, 2026 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding BMRN · SEC Form N-PORT
FundSharesValue% of fundAs of
Dodge & Cox Stock Fund
Dodge & Cox Funds
9.8M$559.0M0.47%Jun 30, 2026
iShares Core S&P Mid-Cap ETF
iShares Trust
6.6M$378.5M0.30%Jun 30, 2026
VANGUARD TOTAL STOCK MARKET INDEX FUND
VANGUARD INDEX FUNDS
6.1M$351.4M0.02%Jun 30, 2026
VANGUARD CAPITAL OPPORTUNITY FUND
VANGUARD HORIZON FUNDS
5.2M$295.7M0.90%Jun 30, 2026
VANGUARD PRIMECAP FUND
VANGUARD CHESTER FUNDS
5.0M$284.4M0.30%Jun 30, 2026
VANGUARD SMALL-CAP INDEX FUND
VANGUARD INDEX FUNDS
4.4M$253.7M0.13%Jun 30, 2026
Capital World Growth & Income Fund2.6M$168.0M0.11%Aug 31, 2026
VANGUARD SMALL-CAP GROWTH INDEX FUND
VANGUARD INDEX FUNDS
2.6M$146.1M0.31%Jun 30, 2026
Fidelity Contrafund2.5M$144.7M0.08%Jun 30, 2026
VANGUARD EXTENDED MARKET INDEX FUND
VANGUARD INDEX FUNDS
2.2M$126.8M0.13%Jun 30, 2026

Mutual funds and ETFs whose N-PORT filings list BMRN's shares (CUSIP 09061G101), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • Viking Global Opportunities Portfolio GP LLCSCHEDULE 13G · passive (13G) · 1.1M shares0.6%
    Nov 20, 2026 · ↗
  • Viking Global Opportunities GP LLCSCHEDULE 13G · passive (13G) · 1.1M shares0.6%
    Nov 20, 2026 · ↗
  • Viking Global Opportunities Parent GP LLCSCHEDULE 13G · passive (13G) · 1.1M shares0.6%
    Nov 20, 2026 · ↗
  • Viking Long Fund Master Ltd.SCHEDULE 13G · passive (13G) · 2.4M shares1.2%
    Nov 20, 2026 · ↗
  • Viking Long Fund GP LLCSCHEDULE 13G · passive (13G) · 2.4M shares1.2%
    Nov 20, 2026 · ↗
  • Viking Global Equities Master Ltd.SCHEDULE 13G · passive (13G) · 5.7M shares2.9%
    Nov 20, 2026 · ↗
  • Viking Global Equities II LPSCHEDULE 13G · passive (13G) · 116.6K shares0.1%
    Nov 20, 2026 · ↗
  • VIKING GLOBAL PERFORMANCE LLCSCHEDULE 13G · passive (13G) · 5.8M shares3.0%
    Nov 20, 2026 · ↗
  • Shabet Rose SharonSCHEDULE 13G · passive (13G) · 9.4M shares4.8%
    Nov 20, 2026 · ↗
  • HALVORSEN OLE ANDREASSCHEDULE 13G · passive (13G) · 9.4M shares4.8%
    Nov 20, 2026 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming BIOMARIN PHARMACEUTICAL INC as client

No lobbying filings found naming BIOMARIN PHARMACEUTICAL INC as the client.

Government Contracts

Federal awards to BIOMARIN PHARMACEUTICAL INC · USAspending

No federal contract awards found for BIOMARIN PHARMACEUTICAL INC.

U.S. Patents

Recent USPTO applications naming BIOMARIN PHARMACEUTICAL INC

No USPTO patent applications found for BIOMARIN PHARMACEUTICAL INC.

Annual Financials

From BMRN's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Revenue$3.22B$2.85B$2.42B$2.10B$1.85B
Operating income$409.5M$484.2M$185.8M$161.0M-$82.3M
Net income$348.9M$426.9M$167.6M$141.6M-$64.1M
Diluted EPS$1.80$2.21$0.87$0.75-$0.35
Operating cash flow$828.0M$572.8M$159.3M$175.9M$304.5M
Cash and equivalents$1.31B$942.8M$755.1M$724.5M$587.3M
Total assets$7.59B$6.99B$6.84B$6.38B$6.00B
Total liabilities$1.51B$1.33B$1.89B$1.77B$1.74B
Shareholders' equity$6.09B$5.66B$4.95B$4.60B$4.27B

As BIOMARIN PHARMACEUTICAL INC tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 26, 2026 ↗

Stock Splits

Every split and reverse split in the price history

No stock splits in BMRN's price history.

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 2.02, 9.01Results of operationsNov 2, 2026
    EDGAR ↗
  • 8-K · Items 2.02Results of operationsOct 6, 2026
    EDGAR ↗
  • 8-K · Items 1.01Material agreementSep 30, 2026
    EDGAR ↗
  • 8-K · Items 8.01Other eventsSep 15, 2026
    EDGAR ↗
  • 8-K · Items 5.02Officer / director changeSep 14, 2026
    EDGAR ↗
  • 8-K · Items 8.01Other eventsSep 1, 2026
    EDGAR ↗
  • 8-K · Items 1.01, 7.01, 9.01Material agreement · Reg FD disclosureAug 31, 2026
    EDGAR ↗
  • 8-K · Items 1.01, 7.01, 9.01Material agreement · Reg FD disclosureAug 18, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsAug 6, 2026
    EDGAR ↗
  • 8-K/A · Items 8.01, 9.01Other eventsJul 13, 2026
    EDGAR ↗

About BIOMARIN PHARMACEUTICAL INC

From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersNOVATO, CA
IncorporatedDE